1.
Balon HR, Goldsmith SJ, Siegel BA, Silberstein EB, Krenning EP, Lang O, Donohoe KJ: Procedure guideline for somatostatin receptor scintigraphy with 111In-pentetreotide. J Nucl Med 2001;42:1134–1138.
2.
Menda Y, Kahn D: Somatostatin receptor imaging of non-small lung cancer with 99mTc depreotide. Semin Nucl Med 2002;32:92–96.
3.
Lebtahi R, Le Cloirec J, Houzard C, et al: Detection of neuroendocrine tumors: (99m)Tc-P829 scintigraphy compared with (111)In-pentetreotide scintigraphy. J Nucl Med 2002;43:889–895.
4.
Patel YC, Greenwood MT, Warszynska A, Panetta R, Srikant CB: All five cloned somatostatin receptors (hSSTR1–5) are functionally coupled to adenylyl cyclase. Biochem Biophys Res Commun 1994;198:605–612.
5.
Hoyer D, Epelbaum J, Feniuk W, et al: Somatostatin receptors; in Girdlestrom D (ed): The IUPHAR Compendium of Receptor Characterization and Classification. London, IUPHAR Media, 2000, pp 354–364.
6.
Sreedharan SP, Kodama KT, Peterson KE, Goetzl EJ: Distinct subsets of somatostatin receptors on cultured human lymphocytes. J Biol Chem 1989;264:949–953.
7.
Reubi JC, Horisberger U, Waser B, Gebbers JO, Laissue J: Preferential location of somatostatin receptors in germinal centers of human gut lymphoid tissue. Gastroenterology 1992;103:1207–1214.
8.
Reubi JC, Schaer JC, Markwalder R, Waser B, Horisberger U, Laissue JA: Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance. Yale J Biol Med 1997;70:471–479.
9.
Csaba Z, Dournaud P: Cellular biology of somatostatin receptors. Neuropeptides 2001;35:1–23.
10.
Reubi JC: Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy. Q J Nucl Med 1997;41:63–70.
11.
Reubi JC, Waser B, Schaer JC, Laissue JA: Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype- selective ligands. Eur J Nucl Med 2001;28:836–846.
12.
Vanhagen PM, Krenning EP, Reubi JC, et al: Somatostatin analogue scintigraphy in granulomatous diseases. Eur J Nucl Med 1994;21:497–502.
13.
Reubi JC, Waser B, Krenning EP, Markusse HM, Vanhagen M, Laissue JA: Vascular somatostatin receptors in synovium from patients with rheumatoid arthritis. Eur J Pharmacol 1994;271:371–378.
14.
Kwekkeboom DJ, de Herder WW, Krenning EP: Receptor imaging in the diagnosis and treatment of pituitary tumors. J Endocrinol Invest 1999;22:80–88.
15.
De Kerviler E, Cadiot G, Lebtahi R, Faraggi M, Le Guludec D, Mignon M: Somatostatin receptor scintigraphy in forty-eight patients with the Zollinger-Ellison syndrome. Eur J Nucl Med 1994;21:1191–1197.
16.
Gibril F, Reynolds JC, Doppman JL, et al: Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 1996;125:26–34.
17.
Krenning EP, Kwekkeboom DJ, Bakker WH, et al: Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1,000 patients. Eur J Nucl Med 1993;20:716–731.
18.
Lebtahi R, Cadiot G, Sarda L, et al: Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 1997;38:853–858.
19.
Kwekkeboom DJ, Krenning EP, Bakker WH, et al: Somatostatin analogue scintigraphy in carcinoid tumors. Eur J Nucl Med 1993;20:283–292.
20.
Kalkner KM, Janson ET, Nilsson S, Carlsson S, Oberg K, Westlin JE: Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radioligand uptake and tumor markers. Cancer Res 1995;55(suppl 23):5801–5804.
21.
Westlin JE, Janson ET, Arnberg H, Ahlstrom H, Oberg K, Nilsson S: Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1]-octreotide. Acta Oncol 1993;32:783–786.
22.
Ahlman H, Wängberg B, Tisell LE, Nilsson O, Fjälling M, Forssell-Aronsson E: Clinical efficacy of octreotide scintigraphy in patients with midgut carcinoid tumours and evaluation of intraoperative scintillation detection. Br J Surg 1994;81:1144–1149.
23.
Kwekkeboom DJ, Van Urk H, Pauw KH, et al: Octreotide scintigraphy for the detection of paragangliomas. J Nucl Med 1993;34:873–878.
24.
Telischi FF, Bustillo A, Whiteman ML, Serafini AN, Reisberg MJ, Gomez-Marin O, Civantos J, Balkany TJ: Octreotide scintigraphy for the detection of paragangliomas. Otolaryngol Head Neck Surg 2000;122:358–362.
25.
Duet M, Sauvaget E, Pételle B, Rizzo N, Guichard JP, Wassef M, Le Cloirec J, Herman P, Tran Ba Huy P: Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck. J Nucl Med 2003;44:1767–1774.
26.
Kwekkeboom DJ, Kho GS, Lamberts SW, Reubi JC, Laissue JA, Krenning EP: The value of octreotide scintigraphy in patients with lung cancer. Eur J Nucl Med 1994;21:1106–1113.
27.
Bombardieri E, Crippa F, Cataldo I, et al: Somatostatin receptor imaging of small cell lung cancer (SCLC) by means of 111In-DTPA octreotide scintigraphy. Eur J Cancer 1995;31A:184–188.
28.
Reisinger I, Bohuslavitzki KH, Brenner W, et al: Somatostatin receptor scintigraphy in small-cell lung cancer: results of a multicenter study. J Nucl Med 1998;39:224–227.
29.
Kirsch CM, von Pawel J, Grau I, Tatsch K: Indium-111 pentetreotide in the diagnostic work-up of patients with bronchogenic carcinoma. Eur J Nucl Med 1994;21:1318–1325.
30.
Haldemann AR, Rosler H, Barth A, et al: Somatostatin receptor scintigraphy in central nervous system tumors: role of blood-brain barrier permeability. J Nucl Med 1995;36:403–410.
31.
Schmidt M, Scheidhauer K, Luyken C, et al: Somatostatin receptor imaging in intracranial tumours. Eur J Nucl Med 1998;25:675–686.
32.
Kwekkeboom DJ, Krenning EP, Kho GS, Breeman WAP, Van Hagen PM: Octreotide scintigraphy in patients with sarcoidosis. Eur J Nucl Med 1998;25:1284–1292.
33.
Postema PTE, Krenning EP, Wijngaarde R, et al: [111In-DTPA-D-Phe1]-octreotide scintigraphy in thyroidal and orbital Graves’ disease: a parameter for disease activity? J Clin Endocrinol Metab 1994;79:1845–1851.
34.
Krassas GE, Dumas A, Pontikides N, Kaltsas T: Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease. Clin Endocrinol (Oxf) 1995;42:571–580.
35.
Zimmer T, Stolzel U, Bader M, et al: Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas. Gut 1996;39:562–568.
36.
Kwekkeboom DJ, Reubi JC, Lamberts SWJ, et al: In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab 1993;76:1413–1417.
37.
Tisell LE, Ahlman H, Wängberg B, et al: Somatostatin receptor scintigraphy in medullary thyroid carcinoma. Br J Surg 1997;84:543–547.
38.
Adams S, Baum RP, Hertel A, Schumm-Draeger PM, Usadel KH, Hör G: Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings. Eur J Nucl Med 1998;25:1277–1283.
39.
Postema PTE, De Herder WW, Reubi JC, et al: Somatostatin receptor scintigraphy in non-medullary thyroid cancer. Digestion 1996;1(suppl):36–37.
40.
Gulec SA, Serafini AN, Sridhar KS, et al: Somatostatin receptor expression in Hurthle cell cancer of the thyroid. J Nucl Med 1998;39:243–245.
41.
Haslinghuis LM, Krenning EP, de Herder WW, Reijs AEM, Kwekkeboom DJ: Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer. J Endocrinol Invest 2001;24:415–422.
42.
Van Eijck CH, Krenning EP, Bootsma A, et al: Somatostatin-receptor scintigraphy in primary breast cancer. Lancet 1994;343:640–643.
43.
Lugtenburg PJ, Lowenberg B, Valkema R, et al: Somatostatin receptor scintigraphy in the initial staging of low-grade non-Hodgkin’s lymphomas. J Nucl Med 2001;42:222–229.
44.
Lugtenburg PJ, Krenning EP, Valkema R, et al: Somatostatin receptor scintigraphy useful in stage I–II Hodgkin’s disease: more extended disease identified. Br J Haematol 2001;112:936–944.
45.
Van der Harst E, de Herder WW, Bruining HA, et al: [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 2001;86:685–693.
46.
Gibril F, Reynolds JC, Chen CC, et al: Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. J Nucl Med 1999;40:539–553.
© 2008 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the...
© 2008 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.